Latest news
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform - The Joplin GlobeThe Joplin Globe · Mon, 03 Aug 2026 13:06:28 GMTVaximm Announces VXM01 Glioblastoma Data Publication Plans - ACCESS NewswireACCESS Newswire · Mon, 03 Aug 2026 13:02:39 GMTVaximm's Two Glioblastoma Studies Had No Dose-Limiting Toxicities - Stock TitanStock Titan · Mon, 03 Aug 2026 13:02:00 GMT